Our mission
Pharma Equity Group is a Pharmaceutical investment Group. Our mission is to support our subsidiary to succeed in developing new effective medicines for the local treatment of serious, acute and chronic inflammatory diseases that have significant consequences for patients and society and for which there is currently no optimal treatment.
Subsidiary Reponex Pharmaceuticals
Reponex Pharmaceuticals is owned by Pharma Equity Group, a company focused on acquiring and developing innovative biopharmaceutical assets. This ownership provides Reponex with the strategic and financial backing to advance its drug development programs, supporting its efforts in creating cutting-edge therapies for unmet medical needs.
The company’s core mission revolves around addressing unmet medical needs through research and development, particularly on novel drug formulations and cutting-edge delivery systems.
The company is dedicated to improving patient outcomes by advancing the science behind its treatments, often leveraging collaborations with academic institutions, research organizations, and other industry leaders. Reponex Pharmaceutical’s development pipeline includes a range of pharmaceutical candidates, primarily within stage 2 of clinical development.
Reponex Pharmaceuticals is likely committed to regulatory compliance, ensuring its products meet the rigorous standards set by authorities such as the FDA or EMA, depending on the regions they serve. Additionally, the company prioritizes patient safety, efficacy, and access, striving to bring innovative therapies to the market that enhance the quality of life for individuals with chronic or life-threatening illnesses.
Our drug development strategy
Local drug administration is very beneficial for patients as it allows for precision targeting. By delivering drugs directly to the specific area of concern, it minimizes systemic exposure to other areas of the body, reducing the risk of side effects and adverse reactions. This approach also means less exposure to metabolic processes in the liver, ensuring that the medication remains more potent and effective where it should. Lower systemic exposure and reduced metabolism translate to lower overall dose requirements, which can be a game-changer for patient safety as the amount of medication they need is reduced. In essence, local administration maximizes therapeutic benefits while minimizing potential risks. This is the foundation of Reponex Pharmaceuticals’ drug development strategy.
Latest news
Stay up to date with the latest stakeholder news, insights and key developments from Pharma Equity Group and its subsidiary Reponex Pharmaceuticals.